Therapeutic alternatives in painful diabetic neuropathy: a meta-analysis of randomized controlled trials
10.3344/kjp.2018.31.4.253
- Author:
Samuel VILAR
1
;
Jose Manuel CASTILLO
;
Pedro V MUNUERA MARTÍNEZ
;
María REINA
;
Manuel PABÓN
Author Information
1. Pain Clinic, University Hospital Virgen del Rocío, Seville, Spain. samuelvilarpalomo@hotmail.com
- Publication Type:Meta-Analysis
- Keywords:
Chronic pain;
Diabetes complications;
Diabetic neuropathies;
Pain;
Pain management;
Pain unit
- MeSH:
Chronic Pain;
Clonidine;
Delivery of Health Care;
Diabetes Complications;
Diabetic Neuropathies;
Duloxetine Hydrochloride;
Pain Management;
Pathology;
Pregabalin
- From:The Korean Journal of Pain
2018;31(4):253-260
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: One of the most frequent problems caused by diabetes is the so called painful diabetic neuropathy. This condition can be treated through numerous types of therapy. The purpose of this study was to analyze, as a meta-analysis, different treatments used to alleviate painful diabetic neuropathy, with the aim of generating results that help making decisions when applying such treatments to tackle this pathology. METHODS: A search was conducted in the main databases for Health Sciences, such as PUBMED, Web of Science (WOS), and IME biomedicina (Spanish Medical Reports in Biomedicine), to gather randomized controlled trials about treatments used for painful diabetic neuropathy. The analyzed studies were required to meet the inclusion criteria selected, especially those results related to pain intensity. RESULTS: Nine randomized controlled trials were chosen. The meta-analysis shows significant positive effects for those treatments based on tapentadol [g: −1.333, 95% CI (−1.594; −1.072), P < 0.05], duloxetine [g: −1.622, 95 % CI (−1.650; −1.594), P < 0.05], pregabalin [g: −0.607, 95% CI (−0.980; −0.325), P < 0.05], and clonidine [g: −0.242, 95 % CI (−0.543; −0.058), P < 0.05]. CONCLUSIONS: This meta-analysis indicates the effectiveness of the treatments based on duloxetine, gabapentin and pregabalin, as well as other drugs, such as tapentadol and topic clonidine, whose use is better prescribed in more specific situations. The results provided can help increase the knowledge about the treatment of painful diabetic neuropathy and also in the making of clinical practice guidelines for healthcare professionals.
